Table 1

Baseline demographic and disease characteristics

PlaceboUstekinumabTotal
45 mg90 mg
Patients, n248248251747
Male128 (51.6)131 (52.8)143 (57.0)402 (53.8)
BMI (kg/m2)30.6±7.530.1±6.530.4±7.130.4±7.0
Disease duration (years)
 PsA6.8±7.76.2±7.66.8±7.76.6±7.7
  <1 year61 (24.6)47 (19.0)40 (15.9)148 (19.8)
  ≥1 to <3 years59 (23.8)72 (29.0)62 (24.7)193 (25.8)
  ≥3 years128 (51.6)129 (52.0)149 (59.4)406 (54.4)
 Psoriasis15.6±12.914.5±12.615.1±12.615.1±12.7
Patients with psoriasis involving ≥3% BSA, n176181189546
 PASI12.0±10.211.9±12.110.7 (8.7)11.5±10.4
 DLQI11.9±7.611.2±7.210.6±7.111.2±7.3
Swollen joint count (0–66)14.7±9.912.6±7.612.8±8.613.4±8.8
Tender joint count (0–68)24.4±14.622.5±14.122.8±13.823.2±14.2
CRP (mg/L)15.6±18.418.1±22.117.4±18.717.1±19.8
HAQ-DI1.24±0.671.22±0.621.21±0.621.22±0.64
DAS28-CRP5.2±1.15.2±1.05.2±1.05.2±1.0
Patients with dactylitis in ≥1 digit113 (45.6)120 (48.4)113 (45.0)346 (46.3)
 Dactylitis score8.3±10.07.8±9.77.9±8.68.0±9.4
Patients with enthesitis176 (71.0)167 (67.3)184 (73.3)527 (70.5)
 Enthesitis score5.2±3.85.1±3.65.7±3.95.3±3.8
SF-36 PCS score31.3±8.631.0±8.431.4±8.031.2±8.3
SF-36 MCS score42.7±11.242.7±11.243.4±11.542.9±11.3
Concomitant MTX use at baseline121 (48.8)127 (51.2)129 (51.4)377 (50.5)
MTX-naïve56 (22.6)58 (23.4)65 (25.9)179 (24.0)
csDMARD-naïve45 (18.1)48 (19.4)53 (21.1)146 (19.5)
  • Data are presented as n (%) or mean±SD unless otherwise noted.

  • BMI, body mass index; BSA, body surface area; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28-CRP, 28-joint count disease activity score using C reactive protein; DLQI, Dermatology Life Quality Index; HAQ-DI, Health Assessment Questionnaire–Disability Index; MTX, methotrexate; PASI, psoriasis area and severity index; SF-36 PCS/MCS, 36-item Short-Form Health Survey physical/mental component summary; PsA, psoriatic arthritis.